Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

Table 2 Multivariate analyses of characteristics associated with overall survival and progression free survival

Variables	OS (n = 110)					PFS (n = 107)
	Original		Variables selected		Bootstrap^c	Original		Variables selected		Bootstrap^c
	HR (95%CI)	P-value^b	HR (95%CI)	P-value^b	P-value^b	HR (95%CI)	P-value^b	HR (95%CI)	P-value^b	P-value^b
Histology
Non-clear cell vs clear cell	2.325 (1.293–4.181)	0.005	2.108 (1.191–3.732)	0.010	0.011	1.717 (1.008–2.926)	0.047	1.606 (0.952–2.710)	0.076	0.087
TNM stage at initial diagnosis
IV vs I–III	0.990 (0.565–1.736)	0.972				0.988 (0.599–1.631)	0.963
No. of metastatic sites^a
≥ 2 vs 1	1.465 (0.867–2.477)	0.154				1.946 (1.210–3.128)	0.006	1.817 (1.138–2.902)	0.012	0.026
Tyrosine kinase inhibitors
Sorafenib vs Sunitinib	1.431 (0.861–2.381)	0.167				1.360 (0.858–2.154)	0.191
Heng’s risk group		<0.001		<0.001	0.005		0.036		0.011	0.035
Favorable	reference		reference			reference		reference
Intermediate	1.955 (0.895–4.268)		2.023 (0.964–4.244)			1.212 (0.634–2.313)		1.297 (0.701–2.398)
Poor	5.654 (2.267–14.103)		6.760 (2.932–15.587)			2.432 (1.095–5.398)		2.771 (1.326–5.788)
Tumoral CCR7
High vs Low	2.242 (1.288–3.901)	0.004	2.256 (1.336–3.809)	0.002	0.003	1.782 (1.105–2.875)	0.018	1.835 (1.156–2.912)	0.010	0.013

Bold data means statistical significant (P<0.05)
HR Hazard Ratio, CI confidence interval, OS overall survival, PFS progression free survival
P-value <0.05 was regarded as statistically significant
^aAt the time initializing tyrosine kinase inhibitors
^bData obtained from the Cox proportional hazards model
^cBootstrapping with 1000 resamples were used

ISSN: 1471-2407